Hypothesis: Age‑dependent epigenetic repression of PXR coactivator recruitment underlies intestinal barrier failure despite preserved microbial indole‑3‑propionic acid (IPA) production

Core proposition In aged intestinal epithelium, PXR retains the ability to bind IPA (Kd ≈ 8.7 µM) but fails to drive transcription of barrier genes because age‑associated increases in histone deacetylase 3 (HDAC3) activity and reduced SRC‑1 coactivator expression shift the PXR‑RXR heterodimer toward a repressive chromatin state. Consequently, exogenous IPA cannot rescue barrier function unless HDAC activity is concurrently inhibited.

It's unlikely that microbial IPA production collapses with age, but we can't assume host responsiveness stays intact.

Novel mechanistic insight Aging is linked to elevated colonic HDAC3 expression (1) and decreased SRC‑1 levels in multiple tissues. We propose that HDAC3 deacetylates lysine residues on SRC‑1 and on histones at PXR‑responsive promoters, preventing coactivator docking and RNA polymerase II recruitment. This creates a “ligand‑bound but transcriptionally silent” PXR state that explains the lack of rescue in aged DSS models reported in the literature.

Testable predictions

1. Co‑immunoprecipitation – In colonic epithelium from 6‑month vs 24‑month mice, IPA treatment will increase PXR‑SRC‑1 interaction in young tissue but not in aged tissue; HDAC3 inhibition (e.g., with RGFP966) will restore the interaction in aged samples.
2. Chromatin acetylation – ChIP‑qPCR for H3K27ac at the ZO‑1, occludin, and claudin‑1 promoters will show reduced acetylation after IPA exposure in aged epithelium, which is rescued by HDAC3 inhibition.
3. Functional barrier assay – Germ‑free aged mice colonized with Clostridium sporogenes will receive: (a) vehicle, (b) IPA alone, (c) IPA + HDAC3 inhibitor, (d) HDAC3 inhibitor alone. Only group (c) will restore transepithelial resistance to ≥80 % of young baseline and increase mucus thickness to >25 µm.
4. Dose‑response shift – In aged tissue, the EC₅₀ for IPA‑induced PXR target gene expression will be right‑shifted (≥2‑fold) compared with young tissue, reflecting reduced coactivator availability; this shift will normalize when HDAC3 is inhibited.

Experimental design outline

• Use male C57BL/6J mice at 6, 12, 18, 24 months (n=6 per group).
• Generate germ‑free cohorts, then mono‑associate with C. sporogenes for 2 weeks.
• Treat with oral IPA (10 mg/kg/day) ± HDAC3 inhibitor (RGFP966, 50 mg/kg/day) for 7 days.
• Measure: serum IPA levels, colonic PXR protein (Western), PXR‑SRC‑1 co‑IP, HDAC3 activity assay, H3K27ac ChIP, ZO‑1/occludin/claudin‑1 mRNA (qPCR), transepithelial resistance (Ussing), mucus thickness ( histology).
• Include PXR‑KO aged mice as negative control.

Falsifiability If aged epithelium shows normal PXR‑SRC‑1 interaction, unchanged promoter acetylation, and IPA alone fully restores barrier function (matching young levels), the hypothesis is refuted. Conversely, if HDAC3 inhibition fails to improve IPA‑mediated barrier rescue despite restoring coactivator binding, alternative mechanisms (e.g., PXR mutation or microbiome metabolite competition) must be considered.

Broader implications Confirming this model would reposition IPA‑based interventions as combinatorial therapies requiring epigenetic adjuvant in older adults, guiding dosing strategies that account for species‑specific PXR sensitivity and age‑related coregulator dysregulation.

References [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12375546/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC11617311/